[8-K] Invizyne Technologies Inc. Reports Material Event

Rhea-AI Filing Summary

Exozymes (Nasdaq: EXOZ) filed an 8-K disclosing entry into the NSF-funded Meta-PURE initiative under the CFIRE program. The three-year cooperative agreement—total award $9.2 million—will deliver about $3 million to Exozymes beginning 1 July 2025.

As the project’s key industrial partner, Exozymes will build a cell-free ATP-generating “power plant” and a production module for high-value fragrance compound santalene. These plug-and-play modules aim to speed reaction times and boost yields across multiple synthetic-biology applications. No additional financial statements, guidance, or dilution were reported.

Positive

• $3 million non-dilutive NSF funding secured via Meta-PURE cooperative agreement commencing July 1 2025 and running three years
• Designation as key industrial partner in a $9.2 million synthetic-biology initiative enhances credibility and potential partnership pipeline

Negative

• None.

Insights

Event Analyst

TL;DR – $3M NSF grant adds non-dilutive capital and tech validation; modest but clearly positive.

The cooperative agreement provides Exozymes with roughly $1 million per year in non-dilutive funding, strengthening cash resources while avoiding equity dilution. Recognition by the NSF and Georgia Tech elevates the firm’s credibility in cell-free biomanufacturing, potentially easing future partnering and grant pursuits. Although the filing lacks revenue metrics, the size of the award appears meaningful for an early-stage platform company and creates a timeline of staged milestone payments that could act as near-term catalysts. Immediate commercial revenue impact is limited, but the technical deliverables—an ATP “power plant” and santalene module—could lead to higher-margin licensing or product opportunities if successfully validated.

Industry Specialist

TL;DR – Grant de-risks R&D, but scale-up economics remain unaddressed.

The Meta-PURE project aligns with market demand for flexible, cell-free production of nutraceuticals and specialty chemicals. Exozymes’ decoupled energy-production module is technically compelling and may shorten development cycles for coalition partners. However, the filing offers no insight into downstream manufacturing economics, IP rights allocation, or revenue-sharing terms—all critical to eventual monetization. Investors should monitor whether the company retains exclusive rights to the ATP module or adopts an open-platform model that could dilute pricing power. Absent cost and margin data, the commercial outlook is still speculative, keeping overall impact neutral to modestly positive.

false 0002010788 0002010788 2025-06-26 2025-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 26, 2025

EXOZYMES INC.

(Exact name of registrant as specified in its charter)

Nevada		001-42204		83-4550057
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

750 Royal Oaks Drive, Suite 106

Monrovia, CA 91016

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (626) 415-1488

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		EXOZ		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 — Entry into Material Agreement.

eXoZymes Inc. (the “Company”) has been selected to participate in the Meta-PURE initiative, a National Science Foundation (“NSF”) funded project under the CFIRE (Cell-Free Systems Toward Increased Range of Use-Inspired Applications) program aimed at transforming the scalability and accessibility of cell-free systems to expand real-world applications. The project coalition of partner enterprises is being led by The Georgia Institute of Technology. Meta-PURE will build a suite of standardized, interoperable ‘modules’ for cell-free biomanufacturing, enabling plug-and-play modules that can rapidly shift between use cases - from high-value nutraceuticals, to essential chemicals or pharmaceuticals. Meta-PURE is part of the CFIRE program and supported under Cooperative Agreement No. 2452482.

eXoZymes will serve as the key industrial partner with Meta-PURE, with an approximate $3 million share of the total project award of $9.2 million. The project will commence July 1, 2025, and will run for three years.

eXoZymes will develop a cell free ATP-generating module - essentially a cell-free power plant - that fuels different chemical production modules to be developed now and in the future, supporting cell-free manufacturing of several market-relevant targets. eXoZymes’s technology permits decoupling the power module from the production module, enabling faster reaction times, greater product yields, and making the development of production modules more accessible for our coalition partners across a broad spectrum of synthetic biology applications. The other coalition partners will develop targets spanning a wide range of complexity and markets, relying on eXoZymes’ plug-and-play cell-free power plant, which will be tested and optimized to both purified and lysate-based exozymes biosolutions to ensure compatibility and performance.

eXoZymes’ role also includes developing a production module for santalene, an extremely high-value fragrance compound, traditionally extracted from sandalwood for use in aromatherapy and traditional medicine formulations. Derivates of santalene have been investigated in pharmaceutical use cases.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits		Description of Exhibit
99.1		Press release dated June 26, 2025 regarding participation in CFIRE program
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	June 26, 2025	EXOZYMES INC.
		By	/s/ Fouad Nawaz
			Fouad Nawaz,
			Vice President, Finance

FAQ

How much funding will EXOZ receive under the Meta-PURE initiative?

The filing states Exozymes will receive approximately $3 million of the total $9.2 million award over three years.

When does the Meta-PURE project start and how long will it last?

The project commences on July 1, 2025 and is scheduled to run for three years.

What is Exozymes’ role in the Meta-PURE coalition?

Exozymes will develop a cell-free ATP-generating module and a production module for the high-value fragrance compound santalene.

Which program funds Meta-PURE and what is its objective?

Meta-PURE is backed by the National Science Foundation’s CFIRE program, aiming to create standardized, plug-and-play cell-free biomanufacturing modules.

Did the 8-K include any financial statements or earnings guidance?

No. The filing focused solely on the material agreement; it did not provide financial statements or forward-looking guidance.